SI2137217T1 - Postopki za inhibiranje vezave endosialina na ligande - Google Patents

Postopki za inhibiranje vezave endosialina na ligande

Info

Publication number
SI2137217T1
SI2137217T1 SI200831213T SI200831213T SI2137217T1 SI 2137217 T1 SI2137217 T1 SI 2137217T1 SI 200831213 T SI200831213 T SI 200831213T SI 200831213 T SI200831213 T SI 200831213T SI 2137217 T1 SI2137217 T1 SI 2137217T1
Authority
SI
Slovenia
Prior art keywords
endosialin
ligands
inhibiting
binding
methods
Prior art date
Application number
SI200831213T
Other languages
English (en)
Inventor
Yuhong Zhou
Brian E. Tomkowicz
Luigi Grasso
Philip M. Sass
Nicholas C. Nicolaides
Original Assignee
Morphotek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek, Inc. filed Critical Morphotek, Inc.
Publication of SI2137217T1 publication Critical patent/SI2137217T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SI200831213T 2007-04-05 2008-04-04 Postopki za inhibiranje vezave endosialina na ligande SI2137217T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US98002607P 2007-10-15 2007-10-15
EP08733125.2A EP2137217B1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (1)

Publication Number Publication Date
SI2137217T1 true SI2137217T1 (sl) 2014-07-31

Family

ID=39714208

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831213T SI2137217T1 (sl) 2007-04-05 2008-04-04 Postopki za inhibiranje vezave endosialina na ligande
SI200831729A SI2620451T1 (sl) 2007-04-05 2008-04-04 Metode za zaviranje vezave endosialina na ligande

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831729A SI2620451T1 (sl) 2007-04-05 2008-04-04 Metode za zaviranje vezave endosialina na ligande

Country Status (20)

Country Link
US (4) US7807382B2 (sl)
EP (2) EP2620451B1 (sl)
JP (2) JP5825784B2 (sl)
KR (1) KR101529334B1 (sl)
CN (1) CN101918446B (sl)
AU (1) AU2008237296B2 (sl)
BR (1) BRPI0809665B8 (sl)
CA (1) CA2682726C (sl)
CY (2) CY1115370T1 (sl)
DK (2) DK2137217T3 (sl)
ES (2) ES2606906T3 (sl)
HR (2) HRP20140266T1 (sl)
HU (1) HUE031269T2 (sl)
LT (1) LT2620451T (sl)
MX (1) MX2009010701A (sl)
PL (2) PL2137217T3 (sl)
PT (2) PT2137217E (sl)
RS (2) RS55447B1 (sl)
SI (2) SI2137217T1 (sl)
WO (1) WO2008124570A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607455A1 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
SI2137217T1 (sl) 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
WO2013148250A1 (en) * 2012-03-30 2013-10-03 Morphotek, Inc. Tem-1 diagnostic antibodies
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
EP2964764A1 (en) 2013-03-09 2016-01-13 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制***的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
ATE244888T1 (de) 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
EP0746613B1 (en) 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
EP1112020A1 (en) 1998-09-09 2001-07-04 U.S. Army Institute of Surgical Research Method for monitoring arterial oxygen saturation
EP1283905A2 (en) 2000-03-15 2003-02-19 Epigenomics AG Diagnosis of diseases associated with the cell cycle
EP1307557A2 (en) 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
EP1351565B1 (en) 2001-01-15 2011-03-16 Morphotek, Inc. Chemical inhibitors of mismatch repair
US20040043928A1 (en) 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
AU2003262717A1 (en) 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CA2518490A1 (en) 2003-03-04 2004-09-16 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
ATE493152T1 (de) 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
AU2005311660B2 (en) 2004-12-03 2011-07-07 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
CA2607455A1 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
RU2008129028A (ru) 2005-12-16 2010-01-27 Дженентек, Инк. (Us) Способ диагностики, прогнозировния и лечения глиомы
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2041307A2 (en) 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
WO2008009132A1 (en) 2006-07-21 2008-01-24 The Governors Of The University Of Alberta Tissue rejection
ES2548690T3 (es) 2006-08-11 2015-10-20 Johns Hopkins University Secuencias consenso de codificación de cánceres colorrectales humanos
US20080300170A1 (en) 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
WO2008097908A2 (en) 2007-02-05 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
SI2137217T1 (sl) * 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
EP2696203A3 (en) 2007-08-16 2014-05-28 The Royal Institution for the Advancement of Learning/McGill University Tumor cell-derived microvesicles
EP4219762A1 (en) 2008-02-01 2023-08-02 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
EP2677041A3 (en) 2008-02-19 2014-04-09 MDxHealth SA Detection and prognosis of lung cancer
WO2009120877A2 (en) 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Also Published As

Publication number Publication date
CA2682726A1 (en) 2008-10-16
EP2137217A1 (en) 2009-12-30
PT2620451T (pt) 2016-12-20
RS53362B (en) 2014-10-31
ES2606906T3 (es) 2017-03-28
JP2013150618A (ja) 2013-08-08
PL2137217T3 (pl) 2014-08-29
US20080248034A1 (en) 2008-10-09
CA2682726C (en) 2017-05-09
BRPI0809665B1 (pt) 2021-03-23
CN101918446A (zh) 2010-12-15
US7807382B2 (en) 2010-10-05
US8895000B2 (en) 2014-11-25
JP5825784B2 (ja) 2015-12-02
JP2010523592A (ja) 2010-07-15
MX2009010701A (es) 2010-01-20
CN101918446B (zh) 2014-06-18
US20110033455A1 (en) 2011-02-10
WO2008124570A1 (en) 2008-10-16
CY1115370T1 (el) 2017-01-04
US20150079104A1 (en) 2015-03-19
HUE031269T2 (en) 2017-06-28
SI2620451T1 (sl) 2017-01-31
CY1118592T1 (el) 2017-07-12
BRPI0809665A2 (pt) 2018-12-04
HRP20161715T1 (hr) 2017-02-10
LT2620451T (lt) 2017-01-10
PL2620451T3 (pl) 2017-06-30
BRPI0809665B8 (pt) 2021-05-25
EP2620451A1 (en) 2013-07-31
US9505842B2 (en) 2016-11-29
AU2008237296B2 (en) 2013-07-04
AU2008237296A1 (en) 2008-10-16
DK2137217T3 (en) 2014-03-17
EP2620451B1 (en) 2016-09-14
KR101529334B1 (ko) 2015-06-16
US10053509B2 (en) 2018-08-21
KR20100016221A (ko) 2010-02-12
PT2137217E (pt) 2014-03-20
EP2137217B1 (en) 2014-03-05
US20170029509A1 (en) 2017-02-02
DK2620451T3 (da) 2017-01-02
RS55447B1 (sr) 2017-04-28
HRP20140266T1 (hr) 2014-04-25
WO2008124570A8 (en) 2008-11-27
ES2452929T3 (es) 2014-04-03

Similar Documents

Publication Publication Date Title
SI2137217T1 (sl) Postopki za inhibiranje vezave endosialina na ligande
FI2637670T4 (fi) Cd3-spesifisten sitoutumisdomeenien aiheuttamien haittavaikutusten estäminen
PT2254579T (pt) Utilização de compostos que se ligam aos ligandos de recetor sigma para o tratamento de dor neuropática que se desenvolve como uma consequência de quimioterapia
EP2117575A4 (en) METHODS AND COMPOSITIONS RELATED TO CLAY ADHESIVES
HK1160110A1 (en) Compounds useful for inhibiting chk1
HK1135417A1 (en) Iron hydrocarbon complex compounds
EP2222343A4 (en) PROCESS FOR SUPPRESSING FASCINE
IL197632A0 (en) Use of jam-c binding compounds
IL212812A0 (en) Ligands that bind il-13
EP2184987A4 (en) BIDENTATE COMPOUNDS AS KINASE INHIBITORS
EP2192904A4 (en) METHODS OF INHIBITING TGF-
IL213675A0 (en) Chiral ligands
ZA201102763B (en) Ligands that have binding specificity for dc-sign
IL212865A0 (en) Chiral ligands
GB0716714D0 (en) Ligands
GB0809888D0 (en) Small molecule inhibition of factor H binding
GB0808069D0 (en) Small molecule inhibition of factor H binding
PL385227A1 (pl) Wkład filtra magnetycznego
ZA201100789B (en) Pyrrolidin-2-ones as hdm2 ligands
GB0809130D0 (en) Corrosion filters
GB0700502D0 (en) Methods to add audio descriptions to controls
GB0715202D0 (en) Improvements to taps
GB0701485D0 (en) Ligands
GB0700576D0 (en) Composition for kidney conditions
GB0905293D0 (en) Agents to prevent binding